Cystic fibrosis - Diagnosis and treatment - Mayo Clinic
Dec 7, 2024 · For those with cystic fibrosis who have certain gene changes, cystic fibrosis transmembrane conductance regulator (CFTR) modulators may help. About 90% of people with CF may be helped by using these medicines.
Cystic fibrosis - Symptoms and causes - Mayo Clinic
Dec 7, 2024 · Cystic fibrosis is a disorder that damages your lungs, digestive tract and other organs. It's an inherited disease caused by a defective gene that can be passed from generation to generation. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices.
What is cystic fibrosis? A Mayo Clinic expert explains
Apr 5, 2022 · Cystic fibrosis is a disorder that damages your lungs, digestive tract and other organs. It's an inherited disease caused by a defective gene that can be passed from generation to generation. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices.
Dornase alfa (inhalation route) - Mayo Clinic
Jan 31, 2024 · Dornase alfa inhalation solution is used together with other medicines (eg, antibiotics, bronchodilators, and steroids) to control symptoms of cystic fibrosis. Cystic fibrosis is a condition in which a thick mucus is formed in the lungs and breathing passages.
A new future for cystic fibrosis - Mayo Clinic
Mar 16, 2017 · We've been fortunate to develop several drug studies that are unique to patients with cystic fibrosis. These unique drug studies are available at very few centers.
Ivacaftor (oral route) - Mayo Clinic
Ivacaftor is used to treat cystic fibrosis (CF). It is only used for patients who have the following mutations in their CF transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, R117H, S1251N, S1255P, S549N, or S549R mutations.
Mayo Clinic Q&A podcast: A milestone in the treatment of cystic …
Jan 29, 2020 · The latest episode of the Mayo Clinic Q&A podcast, features a milestone in the treatment of cystic fibrosis (CF). Tim Myer has lived with cystic fibrosis his whole life. He was awaiting a lung transplant, when a new medication approved by the Food and Drug Administration changed everything.
A milestone treatment for cystic fibrosis - Mayo Clinic News Network
This drug will expand treatment to 27,000, or 90% of all patients with CF in the U.S.," says Dr. Mark Wylam, a Mayo Clinic pulmonologist, and Myer's physician. Myer and Dr. Wylam share the story on this week's Mayo Clinic Q&A podcast.
Elexacaftor, tezacaftor, ivacaftor and ivacaftor (oral route)
For cystic fibrosis: Adults and children 12 years of age and older—2 orange tablets (containing elexacaftor 100 milligrams (mg), tezacaftor 50 mg, and ivacaftor 75 mg) taken in the morning and 1 light blue tablet (containing ivacaftor 150 mg) taken in the evening, about 12 hours apart.
Mayo Clinic's Cystic Fibrosis Foundation-designated CF care center
Mar 3, 2015 · Correctors: Drugs that seek to bring CFTR to the cell surface where none previously existed; Ivacaftor was approved by the Food and Drug Administration (FDA) in 2012 (for ages 6 years and older) for the 4.4 percent of CF patients who have a specific class III G551D mutation.